Charles D Burnette, in Bridgton, ME - Speech-Language Pathologist

Charles D Burnette, is a Speech-language Pathologist based in Bridgton, Maine. Charles D Burnette is licensed to practice in Maine (license number SP2711) and his current practice location is 10 Hospital Dr, Bridgton, Maine. He can be reached at his office (for appointments etc.) via phone at (207) 647-6000.

NPI number for Charles D Burnette is 1578074837 and his current mailing address is 364 Main St, Lewiston, Maine. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1578074837.

Contact Information

	Charles D Burnette,
	10 Hospital Dr, Bridgton, ME 04009-1148
	(207) 647-6000
	(207) 647-6065

Healthcare Provider's Profile

Full Name	Charles D Burnette
Gender	Male
Speciality	Speech-language Pathologist
Location	10 Hospital Dr, Bridgton, Maine
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1578074837
Provider Enumeration Date: 10/13/2017
Last Update Date: 10/13/2017

Medical Identifiers

Medical identifiers for Charles D Burnette such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1578074837	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
235Z00000X	Speech-language Pathologist	SP2711 (Maine)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Charles D Burnette is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Charles D Burnette, 364 Main St, Lewiston, ME 04240-7029 Ph: () -	Charles D Burnette, 10 Hospital Dr, Bridgton, ME 04009-1148 Ph: (207) 647-6000

News Archive

U.S. District Court rules in favor of Alnylam in patent infringement case against Tekmira

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the U.S. District Court of the District of Massachusetts has ruled in favor of Alnylam and has denied Tekmira Pharmaceuticals Corporation's motion to dismiss certain claims and motion to disqualify Alnylam's counsel in an infringement suit filed in January 2012.

Regence introduces flexible health plans for small employers in Oregon

Small employers are traditionally faced with a difficult choice when providing health coverage for their employees: they can either choose benefits that are affordable, or spend more and offer their employees a choice.

First independent test of proposed subphenotypes of COVID-19-related ARDS

In a new paper published online in the Annals of the American Thoracic Society, researchers have been unable to produce two theorized subphenotypes of COVID-19 related acute respiratory distress syndrome (ARDS).

New use of Botox helps voice disorders

An injection that's best known for smoothing wrinkles also helps restore the voices — and the confidence — of people with a voice disorder caused by spasms in their vocal cord muscles, a new University of Michigan study finds.

Infections in older adults may increase risk of hospitalization for dangerous blood clots

Research shows older adults who get infections of any kind - such as urinary, skin, or respiratory tract infections - are nearly three times more likely to be hospitalized for a dangerous blood clot in their deep veins or lungs, University of Michigan Health System research shows.

Charles D Burnette, - Speech-Language Pathologist in Bridgton, ME